Clinical trials: Fungal Skin Infection
Tinea Capitis
Terbinafine Compared to Griseofulvin in Children With Tinea Capitis
Tinea capitis is a dermatophyte infection of the scalp hair follicles, which occurs primarily in children. Hair loss, hair breakage, scaling, plus various degrees of erythema, pustules and pruritus are the primary clinical signs…
- Trial name
- NCT00117767
- Testing
- Terbinafine hydrochloride (HCl), Griseofulvin
- Where
- United States
- Volunteers
- 720 people
- Sponsor
- Novartis Pharmaceuticals
Onychomycosis
Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis
The purpose of this study is to evaluate the safety and efficacy of topical application of IDP-108 versus vehicle in treating patients with onychomycosis.
- Trial name
- NCT01008033
- Testing
- IDP-108, Vehicle
- Where
- 72 sites in United States, Canada and 1 more
- Volunteers
- 870 people
- Sponsor
- Dow Pharmaceutical Sciences
Tinea Pedis
Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis
To demonstrate comparable safety and efficacy of Taro Pharmaceuticals Inc. butenafine hydrochloride cream 1% (test product) and Lotrimin Ultra® cream (reference listed drug) in the treatment of interdigital tinea pedis, and to…
- Trial name
- NCT00835510
- Testing
- Butenafine cream 1% manufactured by Taro, Lotrimin Ultra (butenafine) 1%, Butenafine Vehicle manufactured by Taro
- Where
- 17 sites in United States, Belize
- Volunteers
- 548 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Onychomycosis
Pharmacokinetics and Safety Study of ME1111 in Moderate to Severe Onychomycosis Patients
This study is Randomized, Double-Blind, Vehicle-Controlled, Multiple-Dose Study. The purpose is to determine the safety, tolerability, systemic exposure and pharmacokinetics of ME1111 after repeated daily topical application of…
- Trial name
- NCT01841996
- Testing
- ME1111 solution, Vehicle Solution
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Meiji Seika Pharma Co., Ltd.
Onychomycosis of Toenails
Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail
The purpose of this study is to determine whether AN2690 topical solution is a safe and effective treatment for onychomycosis of the toenail.
- Trial name
- NCT01302119
- Testing
- AN2690 Topical Solution, 5%, Solution Vehicle
- Where
- 32 sites in United States, Canada
- Volunteers
- 604 people
- Sponsor
- Pfizer
Foot Dermatoses
Antifungal Activity of Loceryl Nail Lacquer in Combination With a Cosmetic Varnish
The main objective is to compare efficacy, in terms of antifungal activity of Loceryl Nail Lacquer associated with a Cosmetic Varnish and Loceryl Nail Lacquer alone, in the treatment of mild to moderate toenail Distal Subungual…
- Trial name
- COOL (NCT02321098)
- Testing
- Loceryl NL + Cosmetic varnish, Loceryl NL 12 weeks, Loceryl NL 15 months
- Where
- Iceland
- Volunteers
- 50 people
- Sponsor
- Galderma R&D
Tinea Versicolor
A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.
To demonstrate the efficacy, therapeutic equivalence and safety of Ketoconazole Shampoo, 2% (Taro Pharmaceuticals U.S.A., Inc.) and Ketoconazole 2% Shampoo (Reference Standard) in the treatment of tinea versicolor.
- Trial name
- NCT06305637
- Where
- United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Onychomycosis
Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study
A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi- Site Phase 2b Clinical Study to Assess the Efficacy, Safety and Tolerability of 8-Week Regimens of NVXT topical product in Patients with Mild to Moderate…
- Trial name
- NCT02933879
- Testing
- NVXT topical
- Where
- United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Onychomycosis
Evaluation of the Suitability of PD P 506 A in the PDT of Distal Subungual Onychomycosis (DSO) of the Great Toenail.
This study evaluates the potential usefulness of photodynamic therapy with PD P 506 A in patients with distal subungual onychomycosis of the great toenail.
- Trial name
- NCT02355899
- Testing
- PD P 506 A
- Where
- 2 sites in Germany
- Volunteers
- 25 people
- Sponsor
- photonamic GmbH & Co. KG
Tinea Pedis
Safety and Equivalence of a Generic Ciclopirox Olamine Topical Suspension Compared to the Reference Ciclopirox Topical Suspension 0.77% for the Treatment of Tinea Pedis
The objectives of this study were to demonstrate comparable safety and efficacy of Ciclopirox Olamine Topical Suspension (Test Product) and Ciclopirox Topical Suspension 0.77% (Reference Product) in the treatment of subjects with…
- Trial name
- NCT00804193
- Testing
- Ciclopirox Olamine Topical Suspension, Ciclopirox Topical Suspension 0.77%-Reference Product
- Volunteers
- 553 people
- Sponsor
- Padagis LLC
Tinea Pedis
SB208 for the Treatment of Tinea Pedis
This is a phase 2, multi-center, double-blind, randomized, vehicle-controlled study to be conducted in non immunocompromised adult subjects with interdigital tinea pedis.
- Trial name
- NCT02860052
- Testing
- SB208 2%, SB208 4%, SB208 16%
- Where
- Dominican Republic
- Volunteers
- 222 people
- Sponsor
- Novan, Inc.
Tinea Pedis
Non-inferiority Phase III Trial Comparing Dapaconazole Cream 2% With Ketoconazole Cream 2% in Patients With Tinea Pedis
This is a non-inferiority, Phase III, open-label, randomized, parallel trial to evaluate the new intervention Dapaconazole cream 2% versus Ketoconazole cream 2% in patients with Tinea pedis.
- Trial name
- NCT02606383
- Testing
- Dapaconazole, Ketoconazole
- Where
- Brazil
- Sponsor
- Biolab Sanus Farmaceutica
Tinea Versicolor
A Trial to Evaluate the Safety and Antimicrobial Efficacy of DBI-002 Probiotic in Adults With Tinea Versicolor
A Randomized, Double-Blinded, Aqueous Gel-Controlled Dose Escalating Trial to Study the Safety and Antimicrobial Efficacy of DBI-002 Probiotic vs. Aqueous Gel and Vehicle Gel vs.
- Trial name
- NCT04937920
- Testing
- DBI-002 probiotic gel, Aqueous gel
- Where
- El Salvador
- Volunteers
- 34 people
- Sponsor
- DermBiont, Inc.
Tinea Pedis
A Phase 1b Study of ZYG24004 in Participants With Tinea Pedis Caused by Dermatophytes
This is a multicenter, randomized, double-blind, placebo-controlled Phase 1b study in adult participants with tinea pedis caused by dermatophytes.
- Trial name
- NCT07668999
- Testing
- ZYG24004 1% topical film-forming formulation, ZYG24004 3% topical film-forming formulation
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Sinomune Pharmaceutical Co., Ltd
Onychomycosis
A Study of ATB1651 in Adults With Mild to Moderate Onychomycosis
The study is designed to evaluate the Safety, Tolerability and Pharmacokinetics of ATB1651 in participants with mild to moderate onychomycosis.
- Trial name
- NCT05089409
- Testing
- ATB1651, 2 mg/mL, ATB1651, 5 mg/mL, ATB1651, 10 mg/mL
- Where
- New Zealand
- Volunteers
- 30 people
- Sponsor
- AmtixBio Co., Ltd.
Onychomycosis
TDT 067 Onychomycosis Study
The aim of this study is to establish the efficacy, clinical benefits, and safety of treatment with TDT 067 for clinically diagnosed distal subungual onychomycosis of the toenails caused by dermatophytes confirmed by positive…
- Trial name
- NCT01145807
- Testing
- TDT067, Transfersome
- Where
- United States
- Volunteers
- 738 people
- Sponsor
- Celtic Pharma Development Services
Onychomycosis
A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis
This is a randomized, observer-blinded, Aqueous Gel-controlled trial examining the safety and efficacy of daily application of DBI-001 Gel vs. DBI-002 Gel vs. Aqueous Gel for 24 consecutive weeks in subjects with onychomycosis.
- Trial name
- NCT05491603
- Testing
- DBI-001, DBI-002, Aqueous Gel
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- DermBiont, Inc.
Tinea Corporis
Safety and Efficacy of Product 33525 (Luliconazole Cream 1%) in Pediatric Participants With Tinea Corporis
The objective of this study was to evaluate the safety, efficacy, and pharmacokinetics of luliconazole cream 1% when applied topically for 7 days in pediatric participants 2 years to 17 years of age (inclusive) with tinea…
- Trial name
- NCT02767947
- Testing
- Luliconazole Cream 1%, Vehicle Cream
- Where
- 3 sites in Dominican Republic, Honduras
- Volunteers
- 75 people
- Sponsor
- Bausch Health Americas, Inc.
Tinea Pedis
Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)
To examine the safety and optimal duration of Luliconazole Cream 1% treatments for 14 days or 28 days to achieve "complete clearance" at 2 weeks post treatment.
- Trial name
- NCT00869336
- Testing
- Luliconazole Cream 1% - 2 wks, Luliconazole Cream 1% - 4 wks
- Where
- 4 sites in United States
- Volunteers
- 147 people
- Sponsor
- Tinea Pharmaceuticals
Tinea Pedis
Efficacy and Safety of LAS41003 in the Treatment of Inflammatory Tinea Pedis
The aim of this study is to determine the efficacy and safety of a topical application of the combinational cream LAS41003 compared to application of its mono-substances after once daily treatment in patients with inflammatory…
- Trial name
- NCT01096472
- Testing
- LAS41003, LAS189961, LAS189962
- Where
- 2 sites in Germany
- Volunteers
- 120 people
- Sponsor
- Almirall, S.A.